Small-Molecule Inhibitors of Angiogenesis


The National Cancer Institute's Angiogenesis Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a new set of non-cytotoxic antiangiogenic small molecules. 

Angiogenesis, the growth of new blood vessels from existing vessels, is a normal and vital process in growth and development.  Deregulation of angiogenesis plays a role in many human diseases, including cancer, age-related macular degeneration, diabetic retinopathy, and endometriosis.

NCI investigators have used a cell-based high-throughput screening method to identify a set of anti-angiogenic small molecules.  These compounds are highly active, inhibiting both endothelial cell growth and tube formation, and are not cytotoxic.  Structure-activity relationship analysis has revealed that these compounds are unrelated to known anti-angiogenic compounds, and hence may operate through a novel mechanism of action.  Thus, these compounds would be promising candidates for the development of new anti-angiogenesis therapeutics.



Potential Commercial Applications: Competitive Advantages:
  • Development of new anti-angiogenesis therapeutics.
 
  • These compounds are structurally unrelated to other known anti-angiogenesis compounds, and exhibit high activity without cytotoxicity.


Development Stage:
Pre-clinical (in vivo)

Related Invention(s):
E-281-2007


Inventors:

Enrique Ubani (NCI)  ➽ more inventions...

Frank Cuttitta (NCI)  ➽ more inventions...

Marta Aparico (NCI)  ➽ more inventions...


Intellectual Property:

Collaboration Opportunity:

Licensing only


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-263-2009
Updated: May 4, 2018